


PHARMACEUTICAL 2021

Lexaria Bioscience Corp. Rank 379 of 409







PHARMACEUTICAL 2021

Lexaria Bioscience Corp. Rank 379 of 409



The relative strengths and weaknesses of Lexaria Bioscience Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 226% points. The greatest weakness of Lexaria Bioscience Corp. is the variable Other Expenses, reducing the Economic Capital Ratio by 857% points.

The company's Economic Capital Ratio, given in the ranking table, is -873%, being 518% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	1,926
Cost of Goods Sold	99
Intangible Assets	0
Liabilities, Current	226
Liabilities, Non-Current	120
Other Assets	419
Other Compr. Net Income	0
Other Expenses	3,690
Other Liabilities	0
Other Net Income	0
Property and Equipment	483
Research and Development	387
Revenues	385
Selling, General and Administrative Expense	293

Output Variable	Value in 1000 USD
Assets	2,828
Liabilities	346
Expenses	4,469
Stockholders Equity	2,482
Net Income	-4,085
Comprehensive Net Income	-4,085
Economic Capital Ratio	-873%